4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy

Journal of Immunotherapy

Volumn 37, Issue 4, 2014, Pages 225-236

  Choi, Beom K ^a   Lee, Sang C ^c   Lee, Myoung J ^a   Kim, Young H ^b   Kim, Young Woo ^a   Ryu, Keun Won ^a   Lee, Jun Ho ^a   Shin, Su M ^a   Lee, Sang Ho ^e   Suzuki, Susumu ^d   Oh, Ho S ^c   Kim, Chang H ^c   Lee, Don G ^a   Hwang, Sun H ^a   Yu, Eun Mi ^b   Lee, In O ^a   Kwon, Byoung S ^a,f  

^a National Cancer Center   (South Korea)

^b Biomedicine Production Branch   (South Korea)

^c Personalized Medicine System RandD Center Bio Support Co Ltd   (South Korea)

^d Kosin University College of Medicine   (South Korea)

^e T Cell Technologies Inc   (Japan)

^f TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

4 1BB; EBV; HTERT; Immunotherapy; T cells

Indexed keywords

CD137 LIGAND; CD8 ANTIGEN; CYCLIC GMP; INTERLEUKIN 2; AUTOANTIGEN; CD137 ANTIGEN; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; EPITOPE; MATRIX PROTEIN; PEPTIDE; PHOSPHOPROTEIN; T LYMPHOCYTE RECEPTOR; TELOMERASE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE T CELL THERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PURIFICATION; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL THERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STOMACH CANCER; ANIMAL; CELL SEPARATION; CHEMISTRY; CYTOLOGY; CYTOTOXICITY; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PHENOTYPE; PROCEDURES;

ANIMALS; ANTIGENS, CD137; ANTIGENS, NEOPLASM; AUTOANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; PEPTIDES; PHENOTYPE; PHOSPHOPROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TELOMERASE; VIRAL MATRIX PROTEINS;

EID: 84897979769     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000027     Document Type: Article

References (39)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
2. Klebanoff CA, Khong HT, Antony PA, et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26:111-117.
3. Hill AB, Lee SP, Haurum JS, et al. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med. 1995;181:2221-2228.
4. Smith CA, Ng CY, Heslop HE, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995;4:73-79.
5. Thomas AK, Maus MV, Shalaby WS, et al. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol. 2002;105: 259-272.
6. Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol. 1994;153:996-1003.
7. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20:143-148.
8. Steenblock ER, Fahmy TM. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther. 2008;16:765-772.
9. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
10. Oelke M, Moehrle U, Chen JL, et al. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res. 2000;6:1997-2005.
11. Casares S, Hurtado A, McEvoy RC, et al. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide- MHC class II chimera. Nat Immunol. 2002;3:383-391.
12. Cebecauer M, Guillaume P, Hoza?k P, et al. Soluble MHCpeptide complexes induce rapid death of CD8+ CTL. J Immunol. 2005;174:6809-6819.
13. Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110:201-210.
14. Wolfl M, Kuball J, Eyrich M, et al. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A. 2008;73:1043-1049.
15. Watanabe K, Suzuki S, Kamei M, et al. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int J Hematol. 2008; 88:311-320.
16. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol. 1997;158:2600-2609.
17. Kim YJ, Kim SH, Mantel P, et al. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol. 1998;28:881-890.
18. Vinay DS, Cha K, Kwon BS. Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med. 2006;84:726-736.
19. Wiethe C, Dittmar K, Doan T, et al. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumorassociated antigen. J Immunol. 2003;170:2912-2922.
20. Kim YH, Seo SK, Choi BK, et al. 4-1BB costimulation enhances HSV-1-specific CD8+ T cell responses by the induction of CD11c+CD8+ T cells. Cell Immunol. 2005;238:76-86.
21. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186:47-55.
22. Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev. 2008;222:277-286.
23. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol. 2001;2:415-422.
24. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol. 2001;2:423-429.
25. Riddell SR, Greenberg PD. The use of anti-CD3 and anti- CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128:189-201.
26. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005;46:1-10.
27. Delecluse HJ, Feederle R, O'Sullivan B, et al. Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol. 2007;60:1358-1364.
28. Lee SP, Tierney RJ, Thomas WA, et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol. 1997;158: 3325-3334.
29. Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol. 2000;53:255-261.
30. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005;5:772-782.
31. Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol. 2010;11:21-27.
32. Vonderheide RH, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673-679.
33. Nava-Parada P, Emens LA. GV-1001 an injectable telomerase peptide vaccine for the treatment of solid cancers. Curr Opin Mol Ther. 2007;9:490-497.
34. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
35. Lan P, Tonomura N, Shimizu A, et al. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood. 2006;108:487-492.
36. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
37. Hinrichs CS, Gattinoni L, Restifo NP. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol. 2006;18:363-370.
38. Dudley ME, Gross CA, Langhan MM, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16:6122-6131.
39. Wang X, Berger C, Wong CW, et al. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood. 2011;117:1888-1898.